# Phase 1 Open-label Study of TRX518 Monotherapy and TRX518 in Combination With Gemcitabine, Pembrolizumab, or Nivolumab

> **NCT02628574** · PHASE1 · COMPLETED · sponsor: **Leap Therapeutics, Inc.** · enrollment: 109 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** TRX518 monotherapy
- **DRUG:** TRX518 with gemcitabine
- **DRUG:** TRX518 with pembrolizumab
- **DRUG:** TRX518 with nivolumab

## Key facts

- **NCT ID:** NCT02628574
- **Lead sponsor:** Leap Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01
- **Primary completion:** 2020-07-14
- **Final completion:** 2020-07-14
- **Target enrollment:** 109 (ACTUAL)
- **Last updated:** 2025-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02628574

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02628574, "Phase 1 Open-label Study of TRX518 Monotherapy and TRX518 in Combination With Gemcitabine, Pembrolizumab, or Nivolumab". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02628574. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*